Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence

2.1 Nivolumab (Opdivo, Bristol Myers Squibb) has a UK marketing authorisation 'for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) with tumour cell PD-L1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of MIUC'.

2.2 The dosage schedule is available in the summary of product characteristics for nivolumab.

2.3 The list price of nivolumab is £2,633 per 240 mg per 24‑ml vial (excluding VAT; BNF online, accessed May 2022). The company has a commercial arrangement. This makes nivolumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.